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Abstract
The observation, by Alter et al., of the enrichment of NK cell “escape” variants in individuals
carrying certain Killer-cell Immunoglobulin-like Receptor (KIR) genes is compelling evidence
that natural killer (NK) cells exert selection pressure on HIV-1. Alter et al hypothesise that
variant peptide, in complex with HLA class I molecules binds KIR receptors and either
increases NK cell inhibition or decreases NK cell activation compared to wild type peptide
thus leading to virus escape from the NK cell response. According to this hypothesis, in
order for NK cells to select for an escape variant, an individual must carry both the KIR and
an HLA ligand that binds the variant peptide. In this study we estimate the proportion of the
population that is capable of selecting for escape variants and use both epidemiological
modelling and a model-free approach to investigate whether this proportion explains the
observed variant enrichment. We found that the fraction of individuals within whom the vari-
ant would have a selective advantage was low and was unable to explain the high degree of
enrichment observed. We conclude that whilst Alter et al’s data is consistent with selection
pressure, the mechanism that they postulate is unlikely. The importance of this work is two-
fold. Firstly, it forces a re-evaluation of some of the clearest evidence that NK cells exert a
protective effect in HIV-1 infection. Secondly, it implies that there is a significant aspect of
immunology that is not understood: it is possible that KIRs bind much more widely than
was previously appreciated; that a gene in linkage with the KIR genes is responsible for con-
siderable peptide-dependent selection or that variant peptides are indirectly impacting KIR
ligation.
Author summary
In our opinion, some of the best evidence that natural killer (NK) cells contribute to the
control of HIV-1 infection is the identification of 22 virus variants, “KIR footprints”, that
were hypothesised to escape the NK cell response (Nature, 2011). The authors (Alter,
Heckerman, Schneidewind, Fadda et al) postulate that the variant peptide in complex
with HLA class I molecules modulates the KIR signal and thus reduces recognition of the
virus-infected cell by NK cells. Under this hypothesis, a viral variant can only escape the
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KIR-mediated NK cell response if both the NK receptor (KIR) and its ligand—an HLA
molecule—are present within the host and the viral variant binds to the HLA molecule.
Here we show that this triple requirement severely limits the number of hosts in which a
given virus variant has a selective advantage and, as a result, the authors’ hypothesis is
inconsistent with their reported data. These findings imply that there is a significant
aspect of NK cell immunobiology that we do not understand and calls for a re-evaluation
of the assumption that KIR footprints are evidence for a protective effect of NK cells.
Introduction
Natural killer (NK) cells mediate anti-viral immunity by lysing infected cells, producing pro-
inflammatory cytokines and modulating adaptive immunity. NK cells express activating and
inhibitory receptors; the balance of signals from these receptors determines the NK cell
response. Some of the best studied NK cell receptors are the Killer-cell Immunoglobulin-like
Receptors (KIRs). KIRs are a polymorphic, polygenic family that includes both inhibitory and
activating forms [1]. The ligands for the KIRs include the classical histocompatibility leucocyte
antigen (HLA) class I molecules, which are recognised in broad allotypes. KIRs exhibit a
degree of peptide specificity as amino acid variation in the C-terminal end of peptides pre-
sented by the HLA ligands has been shown to modulate KIR signalling [2–8].
Mounting epidemiological and functional evidence suggests that NK cells play an impor-
tant role in the control of human immunodeficiency virus-1 (HIV-1) infection. Firstly, HIV-1
Nef protein has been shown to downregulate ligands for activating NK receptors from the sur-
face of infected cells (including MICA, ULBP1 and ULBP2 [9–11]). Secondly, soluble ligands
for activating receptors which impair NK cell-mediated cytotoxicity are released during HIV-1
infection [12]. Thirdly, gene association studies show that the gene encoding the NK receptor
KIR3DL1 with the gene for its ligand Bw4-80I and of the gene encoding KIR3DS1 with its
putative ligand Bw4-80I are associated with slower rates of disease progression [13–15] and
reduced risk of infection [16, 17]. Finally, antibody dependent cellular cytotoxicity [18] was
associated with a modest protective effect (odds ratio<1, but not statistically significant) in the
RV144 vaccine trial [18].
More recently, Alter et al studied the relationship between KIR genotype and HIV-1
sequence in a cohort of HIV-1-infected individuals [19]. They identified 22 positions in the
HIV-1 genome at which amino acid polymorphisms were significantly associated with the
presence of specific KIR genes, so-called “KIR-footprints”. They focussed on 6 viral sequence
polymorphisms enriched in KIR2DL2+ individuals compared to KIR2DL2– individuals. In
vitro, variant virus replicates more rapidly than wild type virus in the presence of NK cells
from KIR2DL2+ donors. Alter and co-authors [19–22] postulate that the variant peptide modu-
lates the KIR signal (increasing inhibition for inhibitory KIRs and decreasing activation for
activating KIRs) thus reducing recognition of variant virus-infected cells by NK cells express-
ing the relevant KIR. That is, the variant virus confers escape from NK cells and is selected for,
analogous to the well-documented phenomenon of HIV-1 escape from CD8+ T cells [23–25].
In summary, Alter et al demonstrate that NK cells exert selection pressure on HIV-1 and thus
provide strong evidence that NK cells have direct antiviral effector function in vivo.
However, in order to modulate NK cell activity, the hypothesis of Alter et al requires that
both the KIR receptor and its HLA class I ligand are present. The genes for HLA and KIR are
on different chromosomes and segregate independently [1]. Consequently, a fraction of the
population will have a KIR but will be missing the HLA ligand. Furthermore, for a virus
NK cell selection pressure on HIV-1
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polymorphism to have an inhibitory effect on NK cell function, the variant peptide needs to be
presented by the HLA ligand. A priori, it is not obvious that a sufficient number of people will
meet the triple requirement of having the relevant KIR and having an HLA molecule that both
ligates the KIR and binds the variant peptide. The aim of this study was to quantify the fraction
of the population that meets this triple requirement and then to ascertain whether this fraction
is sufficient to explain the degree of selection observed in the population. The goal is to investi-
gate the hypothesis put forward by Alter and co-authors to explain KIR footprints in HIV-1
sequence and whether such selection would be detected in the population, it is not to investi-
gate the role of NK cells in the control of HIV-1 in general.
Using both in silico epitope prediction (with two independent algorithms) and an in vitro
peptide:HLA stability assay we found that the fraction of the population that was capable of
exerting selection pressure for variant virus was low. Epidemiological modelling shows that
this low fraction of selectors was unable to explain the high degree of enrichment observed. A
simple, model-free approach confirmed this result. We conclude that Alter et al’s data is con-
sistent with selection pressure but that the mechanism that they postulate is unlikely. HLA
class I molecules bind diverse peptides; not enough different HLA molecules bind the same
viral peptide to drive the observed variant enrichment. This calls for a re-evaluation of what
was apparently some of the clearest evidence that NK cells exert a selective effect in HIV-1
infection. Furthermore, it suggests that there is a significant aspect of immunology that we do
not understand: either KIRs bind HLA:peptide much more widely than is currently appreci-
ated; or a gene in linkage with the KIR genes is responsible for significant peptide-dependent
selection; or variant peptides are indirectly impacting KIR ligation.
Results
Variant virus has a selective advantage in a small fraction of the
population
We initially focussed on the 4 viral variants (6 amino acid polymorphisms) studied in depth in
[19]. All 4 variants are enriched in KIR2DL2+ individuals. One of the variant strains, Vpu
(71M/74H) overlaps with Env(17W/20M); there are thus three independent variants: Gag
(138L), Nef(9S) and Vpu(71M/74H)-Env(17W/20M). KIR2DL2 is an inhibitory receptor. It is
postulated that the variant peptide causes stronger inhibitory signalling via KIR2DL2 than
wild type [19–22]. This model requires that the variant peptide binds one or more of the
KIR2DL2-ligating HLA class I molecules and that the amino acid polymorphism either
enhances KIR signalling (i.e. the polymorphism affects KIR-peptide contact) and/or enhances
peptide-HLA binding (i.e. the polymorphism affects ligand availability). We define individuals
who carry both HLA class I and KIR alleles that meet these conditions as ‘selectors’, individuals
where, according to our current understanding of NK cell activation, the variant virus could
have a selective advantage. KIR2DL2 binds HLA C molecules which have an asparagine at
position 80 (designated the C1 group of alleles), HLA-B46:01 and B73:01 (which have a HLA
C-type motif at residues 77–83), and with weaker affinity, HLA C molecules with a lysine at
position 80 (C2 group alleles) [26]. KIRs contact the C-terminal end (specifically positions PC-
1 and PC-2) of the bound peptide [3, 5, 6, 27–29]. We calculated the proportion of selectors in
the HIV-1-infected population in the USA (the population studied by Alter et al [19]), by
using the HLA-gene frequency in different ethnic groups [30], the frequency of these groups
in the HIV-1-infected population [31] and the binding affinity of 8- to 11mer variant peptides
estimated using NetMHCpan v2.8 [32] (Methods).
For Env(17/20) the carrier frequency of selecting HLA class I molecules (fH) was77%
but<40% for the other 4 polymorphisms considered (Table 1, column A rows 1–4). If we
NK cell selection pressure on HIV-1
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relax our definition of what KIR2DL2 can recognise and allow the variant amino acid on all
peptide positions except position 2 and the C-terminal position, which are hidden in the HLA
binding pockets, the frequency of selecting HLAs increases, reaching a median of 42% across
all 6 amino acid polymorphisms (Table 1, column B, rows 1–4). KIR2DL2 mainly binds
HLA-C1 group molecules and has a preference for 9mers [26]. As expected, if we only allow
presentation by HLA-C1 group molecules or analyse binding of 9mers only, the frequency of
selecting HLAs is significantly reduced (Table 1, columns C & D rows 1–4).
Repeating the analysis with an alternative definition of epitope binding (based on the rank
of a variant peptide relative to all other peptides of the HIV-1 proteome [33]; S1 Table and S1
Fig) and with alternative, independent epitope prediction software (Epipred; S2 Table) con-
firmed our finding that the frequency of selecting HLA class I molecules is low.
Next, we extended the analysis to the other viral polymorphisms associated with inhibitory
KIR genes identified in [19]. As for the variants initially focussed on, the frequency of selecting
HLAs for the additional polymorphisms was low (median 14% if we require the polymorphism
at position PC-1 or PC-2, median 26% if we allow the polymorphism at any non-anchor posi-
tion, Table 1, rows 5–6).
In summary, with the exception of Env (17/20), the proportion of the population where the
variant has a selective advantage is low for all of the viral polymorphisms associated with the
presence of inhibitory KIR genes in [19].
Experimental confirmation of poor binding of variant peptide
Prediction of HLA class I-peptide binding using NetMHCpan is now highly accurate and the
magnitude of the discrepancy between experiment and prediction is on a par with discrepan-
cies between laboratories [34]; for HLA-C molecules the algorithm identifies90% of epitopes
at a false positive rate of ~2.5% (M. Nielsen pers. comm.) [35]. Nevertheless, we sought to
experimentally confirm our finding that the majority of HLA C molecules do not stably bind
peptides spanning the polymorphisms of interest using a peptide-MHC class I disassociation
assay [36]. We focussed on one viral polymorphism (Gag 138L) and measured the stability of
8-, 9-, 10- and 11-mers containing this position at the terminal end (PC-1, PC-2 or PC-3) in
complex with all HLA C molecules with an allele frequency0.015. Seven of the ten HLA-C
molecules tested showed no binding to any of the peptides (Table 2). Only HLA-C07:01,
HLA-C07:02 and HLA-C12:03 were able to bind a subset of the peptides and of these, only
Table 1. Frequency of selecting HLA class I molecules in the US HIV+ population (fH). NK cells respond
to (A) mutations at PC-1 (i.e. 1 residue from the C terminus) or PC-2 in peptides presented by any HLA-C,
B*46:01 or B*73:01 molecule, (B) mutations at any position except residue 2 and PC, (C) mutations at PC-1
or PC-2 of 9mers only or (D) mutations at PC-1 or PC-2 in peptides presented by HLA-C1 group molecules
only. HLA molecules are considered to be ‘selecting’ if they bind a variant peptide that obeys the definitions
(A-D) above, or if they do not bind the wildtype peptide but bind at least one variant peptide; the latter figure is
added to give the total frequency of selecting HLAs reported in the table below (see S1 Text for example
calculation).
Frequency of selecting HLAs (fH)
Protein(position) A B C D
Env(17/20) 0.77 0.77 0.04 0.47
Vpu(71/74) 0.30 0.32 0.20 0.30
Gag(138) 0.001 0.02 0 0
Nef(9) 0.37 0.51 0.02 0.35
Tat(3) 0.11 0.11 0.11 0
Vpu(3) 0.17 0.40 0.17 0.17
https://doi.org/10.1371/journal.ppat.1006361.t001
NK cell selection pressure on HIV-1
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one HLA:peptide combination (HLA-C12:03 –SQNYPIVQNLQ) had a half-life of more than
an hour, the suggested minimum stability threshold for immunogenicity [37]. If we use the
experimental measurements for frequent alleles and make the very generous assumption that
all HLA molecules that were not tested bind the peptide then we find that the carrier frequency
of selecting HLAs is fH = 0.136. This estimate represents a maximum upper bound on the fre-
quency of HLA class I molecules selecting for Gag138L.
This experimental work, together with the comprehensive analysis using prediction algo-
rithms, shows that the variant peptide fails to bind most HLA-C molecules. Consequently, the
variant virus will only have a selective advantage in a small fraction of the total population.
Effect of low proportion of selecting individuals on variant enrichment
We next asked whether these low proportions of selecting individuals are sufficient to drive
the enrichment of variant virus in KIR2DL2+ individuals reported by Alter et al. We con-
structed a mathematical model that simulates wild type and variant HIV-1 infection. We con-
sidered the KIR2DL2+ selector population, where the variant has an advantage and escape can
occur, and the KIR2DL2+ non-selector and KIR2DL2– population, where variant virus does
not have an advantage so escape will not occur and there is the possibility of reversion from
variant to wild type virus. A schematic of the model is given in Fig 1, see Methods for details.
We studied the increase of variant virus in the population over time with parameter values
in the centre of the physiological ranges (S3 Table). Assuming an escape rate of 0.1 yr-1 and no
reversion, the model predicts a steady increase in variant virus in both the KIR2DL2+ and
KIR2DL2– population (Fig 2A, solid line). If we increase the escape rate, the fraction of variant
infected people increases faster in both populations (Fig 2A, dashed line); if we increase the
reversion rate, the fraction of variant infected people increases more slowly in both popula-
tions (Fig 2A, dotted line). We find that the fraction of variant-infected people in the modelled
KIR2DL2– population is very similar to that in the KIR2DL2+ population, while in the observed
population there was a significant enrichment of the variant in KIR2DL2+ people. The abrupt
change in the modelled dynamics of variant enrichment in the late 1990s is due to the intro-
duction of combination antiretroviral therapy. Lifespan is extended giving the variant longer
to emerge in selectors and longer to revert in non-selectors.
To investigate if, despite the low frequency of selecting HLAs, any combination of parame-
ters could predict the experimental data we simulated the population dynamics for 100,000
Table 2. Stability of variant peptide:HLA-C complexes. The half-life (in hours) of the peptide: HLA complex is shown. A 0.00 indicates that the signal at
time zero was less than 10% of the positive control and the half-life was too short to be measurable (the peptide is classified as non-binding).
Peptide: HLA half-life (hours)
Sequence C*03:03 C*03:04 C*04:01 C*05:01 C*06:02 C*07:01 C*07:02 C*08:02 C*12:03 C*15:02
YPIVQNLQ 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00
PIVQNLQG 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NYPIVQNLQ 0.00 0.00 0.00 0.00 0.00 0.03 0.18 0.00 0.00 0.00
YPIVQNLQG 0.00 0.00 0.00 0.00 0.00 0.09 0.00 0.00 0.00 0.00
PIVQNLQGQ 0.00 0.00 0.00 0.00 0.00 0.06 0.00 0.00 0.00 0.00
YPIVQNLQGQ 0.00 0.00 0.00 0.00 0.00 0.04 0.15 0.00 0.00 0.00
NYPIVQNLQG 0.00 0.00 0.00 0.00 0.00 0.12 0.20 0.00 0.00 0.00
QNYPIVQNLQ 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NYPIVQNLQGQ 0.00 0.00 0.00 0.00 0.00 0.03 0.14 0.00 0.00 0.00
QNYPIVQNLQG 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00 0.00
SQNYPIVQNLQ 0.00 0.00 0.00 0.00 0.00 0.03 0.17 0.00 1.12 0.00
https://doi.org/10.1371/journal.ppat.1006361.t002
NK cell selection pressure on HIV-1
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random parameter sets taken from realistic ranges for the HIV-1-epidemic in the USA. We
then predicted the enrichment of the polymorphism in the KIR2DL2+ (Fig 2B–2F), and
KIR2DL3+ (Fig 2G) populations in 2010 using the frequency of selecting HLAs (fH) for each
polymorphism (Table 1) and compared this with the experimental data. It is clear that, with
the exception of one of the variants (Env 17/20) out of six, none of the parameter combinations
considered can predict the enrichment of variant virus. Relaxation of the definition of KIR
binding (S2 Fig) as well as variation of the exact definition of variant polymorphism (S2 Text
Additional analysis) confirmed this result.
These results suggest that the enrichment of viral polymorphisms associated with inhibitory
KIR genes cannot be explained by KIR binding of HLA-C molecules presenting variant
epitopes.
Effect of T cell selection pressure
As a positive control, we investigated whether our approach can predict enrichment of CD8+
T cell escape mutations in HLA-matched compared with HLA-mismatched populations. We
considered seven polymorphisms from three published studies [38–40]. We found that the
model could successfully predict enrichment of HLA-associated polymorphisms in all seven
cases (Fig 3). NK cells and T cells differ in many ways. However, the aspect that we are investi-
gating: requirement for presentation of viral peptide by HLA class I molecules, is shared. This
comparison is therefore an appropriate control.
Fig 1. Schematic representation of the mathematical model used to describe viral evolution. We
consider the dynamics of wildtype (WT) and variant (V) virus infection in a population of KIR2DL2+ selectors
(P), KIR2DL2+ non-selectors (M) and KIR2DL2– individuals (X). HIV-1-negative individuals (subscript U), are
born at rate B and can become infected with either WT or V (λWT and λV respectively), at a rate depending on
the prevalence of each strain in the total population. The fraction of KIR2DL2+ people in the total population is
k and the frequency of selecting HLAs is fH. In KIR2DL2+ selectors, virus can escape from WT to V, in the
other two groups V strains can revert to WT. Uninfected individuals die at a rate μ and HIV-1-infected
individuals die at an increased rate α.
https://doi.org/10.1371/journal.ppat.1006361.g001
NK cell selection pressure on HIV-1
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Frequency of selecting HLAs required to explain the observed
enrichment of variant virus in KIR2DL2+ population
We next investigated if increasing the frequency of selecting HLAs (fH) could enable us to pre-
dict the experimentally observed enrichment of variant virus in KIR2DL2+ individuals (S3
Fig). In all cases the enrichment could be predicted provided that the frequency of selecting
HLAs was considerably higher. We found that the enrichment of Gag 138L can be predicted
Fig 2. Fraction of the population infected with variant virus. (A) time course of the fraction of Env-variant-infected
individuals in the KIR2DL2+ (black lines) and KIR2DL2– (grey lines) population from the start of the epidemic for three
different combinations of escape (φ) and reversion (ψ) rates (solid: φ = 0.1yr-1 andψ = 0; dashed: φ = 1yr-1 andψ = 0;
dotted: φ = 0.1yr-1 andψ = 0.05yr-1). The abrupt change in the late 1990s is due to the introduction of combination
antiretroviral therapy. Only 3 combinations of escape and reversion shown for ease of visualisation; a total of 100,000
combinations were considered (B-F) Fraction of variant-infected individuals in the KIR2DL2+ and KIR2DL2– population
for 100,000 randomly chosen parameter values. Grey dots: model predictions, red circle: observation reported by Alter
et al. B: Env, C: Vpu, D: Gag, E: Nef, F: Tat. Model parameters are varied within the ranges given in S3 Table. (G)
Predicted and observed variant enrichment for the KIR2DL3-associated polymorphism in Vpu (3).
https://doi.org/10.1371/journal.ppat.1006361.g002
NK cell selection pressure on HIV-1
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with fH = 25–35%, enrichment of Nef 9S with fH = 50–75%, and enrichment of Vpu 71M/
74H-Env 17W/20M and Tat 3S with fH = 80–100%.
Impact of polymorphisms on peptide processing
Polymorphisms in neighbouring sequences can alter the processing of the peptides they flank
[41]. So another possible explanation for the advantage conferred by a variant is that the muta-
tion increases the production of nearby binding peptides and thus indirectly affects the level of
HLA class I:peptides available for KIR binding. To test this possibility, we used NetMHCpan
to predict the binding of peptides within 20 amino acids of the six polymorphisms (Env(17/
20), Vpu(71/74), Gag(138) and Nef(9)) to HLA-C alleles, HLA-B73:01 and HLA-B46:01 and
found 38 flanking binders. We then used NetCTLPan v1.1 to predict the ability of these pep-
tides to be cleaved and transported with both the variant and the wildtype flanking region. We
found that cleavage was only increased in the presence of the variant for one peptide that
Fig 3. Model predictions for enrichment of CD8+ T cell escape variants. In contrast to the enrichment of
NK cell escape variants in KIR2DL2+ individuals, the enrichment of CD8+ T cell escape variants in HLA-
matched individuals is readily predicted. The 6 panels relate to 7 different reported enrichments of viral
polymorphisms. Variant enriched in individuals carrying (A) HLA-B*27+ [38], (B) HLA-B*51+ [38] (C)
HLA-B*57+ [38] (D) HLA-B*35:01+ [40] (E) HLA-B*51:01+ [40] (F) HLA-B*27+ [39]. Grey dots: model
predictions, red circle: experimental data.
https://doi.org/10.1371/journal.ppat.1006361.g003
NK cell selection pressure on HIV-1
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binds HLA-C15:08. HLA-C15:08 has not been reported in African American, white or His-
panic populations (which together constitute the vast majority of HIV-1-infected individuals
in the US). We conclude that the impact of the polymorphism on flanking peptide processing
is unlikely to contribute to the fraction of selectors in the population.
Polymorphisms associated with activating KIRs
Alter et al also report 14 polymorphism enrichments associated with activating KIRs (aKIRs)
but do not study these variants further (Table 1 in [19]). We extended our analysis to calculate
the frequency of selecting HLAs associated with each of these polymorphisms. An HLA class I
molecule was considered to be selecting if it ligates the activating KIR and either the HLA mol-
ecule binds the wild type but not the variant peptide (variant decreases NK cell activation by
decreasing ligand availability) or the HLA molecule binds at least one wildtype peptide with
the polymorphic position at PC-1 or PC-2 (later extended to any non-anchor position) (i.e.
variant decreases NK cell activation by altering aKIR signalling). As for the inhibitory KIRs, fH
was very low with the exception of one KIR2DS3-associated polymorphism at Vpr37 (S4
Table), indicating that, in the majority of cases the variant strain has a selective advantage in a
small proportion of the population.
Model-independent approach
To check that our conclusions (that the observed variant enrichments were incompatible with
the low proportion of selectors) were independent of the model assumptions we performed a
simple, “model-independent” calculation of the maximum variant enrichment attainable. As a
concrete example consider Tat(3); Fig 4A. The polymorphism at this position is present in
96% of KIR2DL2+ individuals and 67% of KIR2DL2- individuals; the frequency of selecting
HLAs (fH) is 11%. Under the hypothesis of Alter et al, the selection pressure at this position
will be similar in all non-selectors (KIR2DL2+ individuals without the selecting HLA and all
KIR2DL2- individuals); and will be determined by the fitness of the variant in these non-select-
ing hosts. The variant frequency in KIR2DL2- and KIR2DL2+ non-selectors will therefore be
approximately equal at the observed value of 67%. The variant frequency in all KIR2DL2+ indi-
viduals is then
Variant freq in
KIR2DL2þ
individuals
¼
Freq of Variant freq
KIR2DL2þ  in KIR2DL2þ
selectors selectors
2
6
6
6
4
3
7
7
7
5
þ
Freq of Variant freq
KIR2DL2þ  in KIR2DL2þ
non   selectors non   selectors
2
6
6
6
4
3
7
7
7
5
¼ 0:11  v
2
6
6
6
4
3
7
7
7
5
þ ð1   0:11Þ  0:67
2
6
6
6
4
3
7
7
7
5
where v is the variant frequency in KIR2DL2+ selectors. It can readily be seen that even in the
extreme case of 100% frequency of the variant in KIR2DL2+ selectors (v = 1) the maximum var-
iant frequency that can be attained across all KIR2DL2+ individuals is 70.6%, considerably
lower than the observed frequency (96%). Repeating this across all polymorphisms shows a
clear pattern (Fig 4B). All observed variant frequencies (with the exception of the Env:
KIR2DL2 and Vpu:KIR2DS3 polymorphisms already discussed), are systematically higher than
the maximum expected based on the hypothesis of Alter et al (P = 8x10-6). It is striking that the
maximum variant frequency is strongly positively correlated with the observed variant
NK cell selection pressure on HIV-1
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frequency (P = 2x10-12). This is not simply because the maximum variant frequency is corre-
lated with the variant frequency in non-selectors, or with the frequency of selectors since, in a
multivariate linear regression, all 3 variables are independent predictors of the maximum vari-
ant frequency (observed frequency in selectors P = 0.009, observed frequency in non-selectors
P = 2x10-6, fH P = 4x10-10).
Discussion
NK cell inhibition or activation via KIRs is determined by HLA class I ligands that bind the
KIR receptors and, to a lesser extent, by the sequence of the peptides presented by these ligands
[2–8]. Under the hypothesis of Alter et al [19–22], a necessary (but not sufficient) condition
for a host to exert KIR-mediated selection pressure for a given variant is possession of an HLA
class I molecule that ligates the KIR in question and presents the variant peptide. We calculated
the proportion of hosts meeting this condition and investigated whether it was consistent with
the enrichment of variant virus previously reported [19]. We found that the proportion of the
population that can select for the variant is low and is insufficient to explain the observed
Fig 4. Model-independent approach. (A) Schematic. Under the hypothesis of Alter et al the frequency of
the variant in KIR2DL2+ non-selectors and KIR2DL2- non-selectors will be similar (orange; 67% for the
example of Tat(3)). Even if the frequency of the variant in KIR2DL2+ selectors is 100% (green) it is trivial to
see that, because of the low frequency of selectors amongst the KIR2DL2+ population, the variant frequency
amongst the whole KIR2DL2+ population is low and is similar to that of the KIR2DL2- population. (B) Results.
The maximum variant frequency expected (blue) is systematically lower than the observed variant frequency
(red) for the majority of the polymorphisms described by Alter et al. The exceptions are Env 17/20:KIR2DL2
and Vpr 37:KIR2DS3 already discussed. Shading indicates that the expected variant frequency can be lower
(but not higher) than the maximum variant frequency, i.e. variant frequency can take any point in the shaded
region depending on the variant frequency in selectors, the maximum is attained when variant frequency in
selectors is 100% (solid blue line).
https://doi.org/10.1371/journal.ppat.1006361.g004
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enrichment of the variant polymorphism in the KIR2DL2+-population for all but one of the 6
polymorphisms focussed on by Alter et al [19]. Extension to the other 13 polymorphisms asso-
ciated with inhibitory and activating KIR genes showed identical behaviour. A simple, “model-
independent” approach confirmed this finding. The problem is very simple: the frequency of
HLA class I molecules that bind a given KIR and that are capable of exerting selection pressure
at the same amino acid position is too low to explain the variant enrichment seen in the popu-
lation. This is not to say that selection pressure is low, but that in different people with different
HLA molecules, selection pressure will be exerted at different points in the virus genome. So,
on studying virus sequence in the whole population, a signal would not be detected since any
given amino acid would only be under selection pressure in a minority of individuals. Further-
more, not all individuals who have the potential to select for an NK escape variant will do so,
further reducing the variant enrichment. In order to predict the observed variant enrichment
the proportion of selectors needs to be considerably higher.
KIR-HLA:peptide ligation requires two steps: binding of the peptide to the HLA molecule
and ligation of the HLA:peptide complex by KIR. Here we focus on HLA:peptide binding, a
necessary but not sufficient step for HLA:peptide-KIR binding. HLA-peptide binding is well-
characterised and tractable both with experimental and in silico techniques; less is known
about KIR ligation by the HLA-peptide complex. We therefore assume that all HLA:peptide
complexes will trigger KIR. This will overestimate the fraction of selectors. The finding that we
cannot predict the observed variant enrichment even with this overestimated proportion of
selectors underscores the discrepancy between the hypothesis of Alter et al and their observed
experimental data.
Our estimate of the proportion of the population that could select for variant virus depends
on binding prediction algorithms. The algorithm that we use (NetMHCpan v2.8) is a highly
accurate quantitative predictor, with an error comparable to experimental error [32, 34, 42,
43]. We also predict HLA-peptide binding using an independent prediction algorithm,
Epipred. Epipred and NetMHCpan use different methods (logistic regression and artificial
neural networks respectively) and are trained on different experimental data sets. Both these
methods predict poor binding of variant peptides to the HLA ligands of the KIRs of interest.
Additionally, poor binding of a subset of 11 variant peptides to 10 HLA-C molecules (total of
110 combinations) was confirmed experimentally using a peptide:MHC class I dissociation
assay. Of note, two assumptions we made in estimating the fraction of selecting HLAs (that
gene frequencies add linearly and that all amino acid changes will enhance KIR signalling) will
both err on the side of caution and inflate the frequency of selecting HLAs. In reality, the true
frequency will tend to be less than this estimate. We also explored the possibility of variants
enhancing the cleavage of flanking epitopes compared to the wildtype but found that this
could not explain the observed enrichment either.
In summary, we show that, of the 22 viral polymorphism enrichments associated with KIR
genes listed in [19], 19 could be analysed; of these a total of 16 could not be explained by the
hypothesis of Alter et al. A minority (3/19) could be explained, consistent with isolated exam-
ples of NK cell escape reported in the literature e.g. [22]. How else could the KIR-associated
enrichment be explained for the remaining 16 polymorphisms? For concreteness, consider the
example of the KIR2DL2-associated polymorphisms, similar arguments follow for the other
KIRs. Variant enrichment in KIR2DL2+ individuals implies either that the enrichment is
driven by a gene in linkage with KIR2DL2 rather than KIR2DL2 itself or that KIR2DL2 binds
far more widely than has previously been appreciated or that variant peptides are indirectly
impacting KIR ligation. We consider each of these possibilities in turn. KIR2DL2 is in strong
positive linkage with KIR2DS2, an activating KIR gene. Alter et al investigate the possibility
that KIR2DS2 rather than KIR2DL2 is the selecting molecule but discount it because of greater
NK cell selection pressure on HIV-1
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variant enrichment in KIR2DL2+ compared with KIR2DS2+ individuals. However, due to the
extremely tight linkage between the genes and the size of their cohort (N = 91) it is difficult to
make this statement with confidence. However, KIR2DS2 fails to explain the data for exactly
the same reason that KIR2DL2 does; the fraction of people with ligating HLA that also bind
the wild type peptide is very low. KIR2DL2 is also in linkage with other KIR genes. We consid-
ered whether KIR2DL2-related variants could also exert a selective advantage via KIR2DL1 or
KIR2DL3, depending on the HLA-C restriction of the variant peptide. This would theoretically
give rise to a group of KIR2DL2- individuals who would nevertheless also select for the escape
variant. Under such an assumption, the proportion of both KIR2DL2+ and KIR2DL2- variant
carriers would be higher, which would result in a less-pronounced enrichment in KIR2DL2+
individuals; again failing to predict the data. Looking beyond the KIR receptor complex the
next gene cluster is the human leukocyte immunoglobulin-like receptor (LILR) family [44].
The LILR have been linked with outcome in HIV-1 [45], show peptide specificity and bind
HLA molecules more broadly than KIR [44]. They are therefore an ideal candidate to explain
the observed selection, which was attributed to KIR2DL2. However, although the LILR are sep-
arated from the KIR by only 450 kb, linkage between them is weak [46] and is probably insuffi-
cient to drive the observed variant enrichment in KIR2DL2+ individuals. Furthermore,
although Alter et al do not investigate the molecular mechanism underlying the NK cell escape
they describe, they do present some limited functional work showing that a KIR2DL2-IgG
fusion construct binds more strongly to Env-variant infected cells compared with wild type
implying a direct role for KIR2DL2 rather than a genetically linked molecule. If linkage does
not explain the variant enrichment, an alternative hypothesis is that KIR2DL2 binds more
widely than is currently realised. We considered the possibility that KIR2DL2 could bind to
peptide:HLA complexes which were bound with very low affinity. Nevertheless, there is a limit
to how low the affinity of peptide for HLA can be as affinity and stability are closely related
and the complex needs to be sufficiently stable to be presented on the cell surface. We have
already considered peptides that bind with affinity as low as 500nM or rank<2% but still
found an insufficient fraction of selectors. Recently, it was reported that a considerable fraction
of self-peptides presented on HLA are spliced [47]. The mechanism behind this splicing has
not yet been elucidated and it is not known whether spliced viral peptides are also presented. If
spliced HIV-1 peptides are presented this could potentially increase the number of selectors.
Another explanation is that the virus variants indirectly affect KIR-HLA binding by affecting
HLA C expression levels. It has been shown that different HIV-1 strains downregulate surface
HLA-C expression differentially [48]; related to this it is notable that all of the inhibitory KIR
footprints identified by Alter and co-authors relate to lineage III KIRs which bind HLA C mol-
ecules rather than lineage II KIRs which bind HLA-A and -B. However, it is difficult to under-
stand how many different polymorphisms in multiple proteins could all be implicated in HLA
C downmodulation.
Our estimates of the fraction of selectors and epidemiological model to predict variant
enrichment accurately reproduced published works on CD8+ T cell-mediated immune pres-
sure on HIV-1; since the aspect of NK cell selection which we are modelling (requirement for
presentation of viral peptide by HLA class I molecules) is shared by both NK cells and CD8+ T
cells, this is an appropriate control. The conclusion, that our model of the hypothesis of Alter
et al cannot predict the KIR-associated variant enrichment, demonstrates that an aspect of the
KIR-HIV-1 interaction outside their hypothesis is involved. We suggest that, if this additional
aspect were included in the model, then the model would successfully predict the observed var-
iant enrichment. It is important to stress that we are not investigating the role of NK cells in
controlling HIV-1 infection in general. There are a large number of studies convincingly
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demonstrating that NK cells are protective in HIV-1 [9–17]. We are focusing on whether this
would result in selection that would be detectable at the population level.
We conclude that whilst Alter et al’s data is consistent with selection pressure, the postu-
lated hypothesis is insufficient to explain the data. This forces a re-evaluation of the evidence
that NK cells exert selection pressure in HIV-1 [19] and excitingly, suggests that there is a sig-
nificant aspect of KIR immunobiology that we do not understand.
Methods
Prediction of HLA:Peptide binding
The binding of variant and wild type peptides from HIV-1 proteins to HLA class I molecules
was calculated using NetMHCpan v2.8 [34] (S4 Fig). We considered a peptide to be a binder if
its predicted binding falls within the top two percent of a set of 200,000 random natural pep-
tides or has affinity<500nM. We repeated the analysis using an alternative definition of a
binder, namely a peptide is considered to be a binder if its affinity lies within the top 10% of
HIV-1-derived peptides [33]. Calculations were also repeated using independent prediction
software Epipred [49]. Epipred and NetMHCpan use different methods (logistic regression
and artificial neural networks respectively) and are trained on different experimental data sets.
Experimental measurement of peptide-HLA-I complex stability
The stability of 8-, 9-, 10- and 11-mers containing Gag 138L at the terminal end (PC-1, PC-2
or PC-3) in complex with HLA molecules with an allele frequency0.015 in the HIV-
1-infected population was measured as previously described [36]. Briefly, recombinant, dena-
tured and biotinylated MHC-I alpha chain (50-200nM) was diluted in PBS/0.1% Lutrol F68
containing 10μM of peptide and trace amounts of 125I radiolabeled β2m in 384 well streptavi-
din coated scintillation microplates (Streptavidin FlashPlate HTS PLUS SMP410001PK, Perkin
Elmer). Flashplates were incubated over night to attain peptide-HLA-I complex folding. Pep-
tide-HLA-I complex dissociation was initiated by adding excess of unlabeled β2m (200nM)
and transferring the plate to a TopCount NXT Liquid Scintillation Reader (Perkin Elmer) at
37˚C. The plate was read continuously for 24 hours. The peptide off-rate was calculated
according to an exponential decay equation: Y = Y0e^(-kx), where x is the time in hours and
k is the off-rate (complex half-lives were calculated by T½ = ln(2)/k). Relevant positive controls
were included for each HLA-I molecule. Peptides were categorised as not binding if the signal
intensity at time point 0 was less than 10% of the relevant positive control.
Determination of selecting HLA molecules
An HLA molecule was said to be capable of selecting for an inhibitory KIR-associated variant
if 1) the HLA molecule ligates the relevant iKIR and 2i) the variant peptide was predicted to
bind the HLA molecule and had a polymorphism in a position that would interact with the
KIR receptor (initially considered to be PC-1 or PC-2, later relaxed to any non-anchor posi-
tion) or 2ii) the HLA molecule binds none of the wild type peptides and at least one of the vari-
ant peptides containing the variant position. An HLA class I molecule was considered to be
capable of selecting for an activating KIR-associated variant if 1) the HLA molecule ligates the
relevant aKIR and either 2i) the HLA molecule binds at least one wild type peptide with the
polymorphic position at PC-1 or PC-2 (later extended to any non-anchor position) (i.e. variant
decreases NK cell activation by altering aKIR signalling) or 2ii) the HLA molecule binds the
wild type but not the variant peptide (variant decreases NK cell activation by decreasing ligand
availability).
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Since we were unable to reliably predict whether an amino acid change enhanced KIR sig-
nalling we made the generous assumption that any change at PC-1 (i.e. 1 residue from the C
terminus) or PC-2 (later relaxed to any change at any non-anchor position) will enhance sig-
nalling. This assumption will lead to an overestimate of fH, i.e. we are erring on the side of cau-
tion. See S1 Text for an example of selecting HLA molecules.
Calculation of the frequency of selecting HLA molecules in the US HIV-
1-infected population
The frequency of selecting HLA molecules (fH) for a given KIR-associated polymorphism is
estimated by first add up the gene frequency of selecting HLA alleles in each ethnic group (this
will double count people who carry more than one selecting allele and will thus overestimate
fH erring on the side of caution). We then determined the population frequency of selecting
HLAs for each ethnic group using:
fHi ¼ xið1   xiÞ þ ð1   xiÞxi þ x
2
i
Where fHi is the carrier frequency of selecting HLAs in ethnic group i and xi is the frequency of
genes coding for selecting HLA class I molecules in that ethnic group [30]. Next, we multiplied
the carrier frequency of selecting HLAs in one ethnic group with the frequency of the group in
the HIV-1-infected population [50] and finally summed over all ethnic groups to give the car-
rier frequency of selecting HLAs in the HIV-1-infected population (fH)
fH ¼
X
i
fHi : freqðiÞ
Model of viral evolution
We used a model of viral evolution based on [51]. For the sake of clarity we describe the model
for studying polymorphisms enriched in the KIR2DL2+ population; the same model can be
generalised to any KIR of interest. We describe 9 populations of individuals: individuals who
are KIR2DL2+ and carry one or more selecting HLA who are uninfected (PU), wild type (WT)-
infected (PWT) or variant (V)-infected (PV), KIR2DL2+ without selecting HLA who are unin-
fected (MU), WT-infected (MWT) or V-infected (MV) and KIR2DL2– uninfected (XU), WT-
infected (XWT) or V-infected (XV). NK cells can drive escape in KIR2DL2+ individuals with
selecting HLA (PWT), reversion can occur in V-infected KIR2DL2+ hosts without selecting
HLA and in KIR2DL2– individuals (MV and XV). The model is described by 9 ordinary differ-
ential equations:
_PU ¼ fHkB   ðlWT þ lV þ mÞPU
_PWT ¼ lWTPU   PWT   a1PWT
_PV ¼ lVPU þ PWT   a2PV
_MU ¼ ð1   fHÞkB   ðlWT þ lV þ mÞMU
_MWT ¼ lWTMU þ cMV   aMWT
_MV ¼ lVMU   cMV   aMV
_XU ¼ ð1   kÞB   ðlWT þ lV þ mÞXU
_XWT ¼ lWTXU þ cXV   aXWT
_XV ¼ lVXU   cXV   aXV
NK cell selection pressure on HIV-1
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where fH is the carrier frequency of selecting HLA class I molecules in the HIV-1-infected US
population, k is the fraction of KIR2DL2+ individuals in the US population, B is the birth rate
in the US, μ is the death rate of uninfected individuals, α, α1, α2 are the death rates of HIV-
1-infected individuals (see below for details), Φ is the escape rate of WT virus to V and ψ is the
reversion rate from V to WT. Infection rates λWT and λV are defined as:
lWT ¼
b
N
ðPWT þMWT þ XWTÞ
lV ¼
b
N
ðPV þMV þ XVÞ
where β is transmission probability and N is the size of the total population. Simulations are
run from the time of first infection in the US (t0) until 2010. At the introduction of combina-
tion antiretroviral therapy (cART) in 1996, the death rate of HIV+ individuals (α) and trans-
mission probability (β) change. The impact on mortality of HIV-1 escape from the NK cell
response is unknown. Two schemes were considered:
1. A selector with escape variant virus has a mortality disadvantage compared to all other indi-
viduals (α1 = α<α2).
2. A selector with wild type virus has a mortality advantage compared to all other categories of
HIV-1-infected individuals (α1<α2 = α).
The fraction of V infected individuals in the KIR2DL2+ population is calculated as:
f ¼
PV þMV
PV þMV þ PWT þMWT
To investigate impact of parameter choice, the model was run for 100,000 random parameter
sets taken from realistic parameter ranges for the HIV-1-epidemic in the USA.
Parameter values are given in S3 Table, a schematic of the model is presented in Fig 1.
Model-independent estimate of maximum variant enrichment
The variant enrichment in a KIR+ population will depend on the variant enrichment in selec-
tors and non-selectors in that population vis
Variant freq in
KIRþ
individuals
¼
Freq of Variant freq
KIRþ  in KIRþ
selectors selectors
2
6
6
6
4
3
7
7
7
5
þ
Freq of Variant freq
KIRþ  in KIRþ
non   selectors non   selectors
2
6
6
6
4
3
7
7
7
5
The frequency of KIR+ selectors and non-selectors is calculated as described above (“Calcu-
lation of the proportion of selectors in the US HIV-1-infected population”). The variant fre-
quency in KIR+ non-selectors will be similar to KIR- non-selectors and has been measured
experimentally and reported in Alter et al. We therefore know 3 of the 4 terms on the right
hand side of the equation above, the only unknown is “variant frequency in KIR+ selectors”.
The maximum variant enrichment in KIR+ individuals will be attained when the “variant fre-
quency in KIR+ selectors” is maximised i.e. 1.
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Supporting information
S1 Text. Selecting HLA molecules: A worked example.
(DOCX)
S2 Text. Supplementary analysis.
(DOCX)
S1 Table. Fraction of selecting HLAs based on rank definition of an epitope (NetMHC-
pan). An alternative definition of whether a peptide binds an HLA molecule is the rank of its
binding affinity compared to the binding affinity of all peptides from the viral proteome. The
idea is that only viral peptides in the top 5 or 10 binders for a single HLA molecule will be com-
petitive [33]. Table below shows the median and minimum rank of the variant peptide with
the highest affinity relative to the whole HIV-1 genome, the number of HLA alleles for which
the highest ranking peptide falls into the top 5 or top 10 of the whole HIV-genome and the car-
rier frequency of selecting HLAs (fH) based on this definition.
(DOCX)
S2 Table. Fraction of selecting HLAs based on rank definition of an epitope (Epipred). The
carrier frequency of selecting HLAs (fH) was calculated using an alternative, independent epi-
tope prediction algorithm Epipred. Results are tabulated below.
(DOCX)
S3 Table. Parameter values for the model of viral evolution.
(DOCX)
S4 Table. Frequency of selecting HLA’s for polymorphisms associated with activating KIR.
HLA ligands of many of the activating KIRS are unknown and/or contentious. We therefore
considered all commonly assumed ligands (column “assumed HLA ligand”). KIR2DS5 is
believed to have evolved from an activating C2 receptor but appears to have lost the capacity to
bind HLA class I [52]; the two polymorphisms identified by Alter et al as associated with
KIR2DS5 were therefore excluded from our analysis. Additionally, a third polymorphism
identified by Alter et al (Env 46 KIR3DS1) was excluded as we were unable to identify the vari-
ant amino acid.
(DOCX)
S1 Fig. Rank of binding affinity for peptides containing amino acid polymorphisms. How
strongly a peptide binds an HLA molecule relative to other peptides of the HIV-1 proteome
reflects its competitiveness for presentation [33]. Predictions of HLA:peptide binding affinity
were made for all 8- to 11mer peptides from the whole HIV-1 (NL4-3) genome using
NetMHCpan v2.8. Peptides were ranked by affinity and, for each HLA allele, the highest rank-
ing peptide containing the amino acid polymorphism is plotted. The horizontal line indicates
rank 10. It can be seen that, with the exception of one HLA molecule which binds a peptide
containing the polymorphism in Env, the variant peptides are very poor competitors for bind-
ing.
(PNG)
S2 Fig. Enrichment of variant strain in KIR+ and KIR- individuals: Experimental observa-
tion and theoretical prediction. Predicted variant strain enrichment based on the more gen-
erous definition of the frequency of selecting HLAs (Table 1, column B) obtained if we relax
our definition of what KIRs can bind. Grey dots: predicted enrichments obtained by randomly
varying parameters within the range given in S3 Table, red circle: the observed enrichment.
Even with this generous definition of a selecting HLA there are no parameter combinations
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which can match the experimental data for 4 of the 6 variants considered. Panels (A-F) corre-
spond with panels B-G from Fig 2. i.e. (A-E) Fraction of variant-infected individuals in the
KIR2DL2+ and KIR2DL2– population for 100,000 randomly chosen parameter values. Grey
dots: model predictions, red circle: observation reported by Alter et al. A: Env, B: Vpu, C: Gag,
D: Nef, E: Tat. (F) Predicted and observed variant enrichment for the KIR2DL3-associated
polymorphism in Vpu (3).
(TIF)
S3 Fig. Impact of varying the fraction of selecting HLAs. Predicted fraction of variant-
infected individuals in the KIR2DL2+ and KIR2DL2– population for different fractions of
selecting HLAs (fH) in the population. The fraction of selecting HLAs was varied (represented
by different colours). The black circles represent the experimentally observed variant enrich-
ment for the 6 variants. In all cases the observed enrichment can be predicted but only if the
fraction of selectors is significantly higher than observed in the population.
(PNG)
S4 Fig. Comparison of variant and wild type binding. Predicted binding of all 8-, 9-, 10-,
11-mers containing the variant position to all KIR ligating HLA molecules (i.e. all HLA C mol-
ecules, B73:01 and B46:01 for the KIR2DL2-associated variants and all HLA C1 molecules,
B73:01 and B46:01 for the KIR2DL3-associated variant). The blue lines denote the point cor-
responding to 500nM (1-log50,000(500) = 0.426), peptide-HLA interactions below this thresh-
old are considered to be non-binding. The red line is the line of equality (x = y).
(TIF)
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